CIK 0001815442
- Large accelerated filer
Kymera Therapeutics, Inc.
Sign in to watch- Ticker
- KYMR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 812992166
- Phone
- +1 857-285-5314
- Business address
- 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
- Former names
- Kymera Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,158,214
- in 2 filings, $3.4M under 10b5-1 plans
Net −$4,158,214. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 68 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-05-26 | BVF PARTNERS L P/IL Director | Purchase | +90,372 | $14.21 | $1.3M | 1,601,575 |
| 2022-05-26 | BVF PARTNERS L P/IL Director | Purchase | +10,642 | $14.21 | $151K | 227,414 |
| 2022-05-20 | BVF PARTNERS L P/IL Director | Purchase | +5,883 | $14.00 | $82K | 2,036,860 |
| 2022-05-20 | BVF PARTNERS L P/IL Director | Purchase | +4,180 | $14.00 | $59K | 1,511,203 |
| 2022-05-20 | BVF PARTNERS L P/IL Director | Purchase | +37 | $14.00 | $518 | 216,772 |
| 2022-05-06 | BVF PARTNERS L P/IL Director | Purchase | +55,210 | $19.26 | $1.1M | 2,030,977 |
| 2022-05-06 | BVF PARTNERS L P/IL Director | Purchase | +40,659 | $19.26 | $783K | 1,507,023 |
| 2022-05-06 | BVF PARTNERS L P/IL Director | Purchase | +4,131 | $19.26 | $80K | 216,735 |
| 2022-05-05 | BVF PARTNERS L P/IL Director | Purchase | +75,495 | $19.60 | $1.5M | 1,975,767 |
| 2022-05-05 | BVF PARTNERS L P/IL Director | Purchase | +70,439 | $19.60 | $1.4M | 1,466,364 |
| 2022-05-05 | BVF PARTNERS L P/IL Director | Purchase | +4,066 | $19.60 | $80K | 212,604 |
| 2022-05-04 | Gollob Jared Chief Medical Officer | Exercise or conversion | +10,208 | $1.31 | $13K | 47,465 |
| 2022-05-04 | Gollob Jared Chief Medical Officer | Exercise or conversion | +9,792 | $2.08 | $20K | 57,257 |
| 2022-05-04 | Gollob Jared Chief Medical Officer | Exercise or conversion · Stock Option (Right to Buy) | −10,208 | 29,799 | ||
| 2022-05-04 | Gollob Jared Chief Medical Officer | Exercise or conversion · Stock Option (Right to Buy) | −9,792 | 109,020 | ||
| 2022-05-03 | Mainolfi Nello Chief Executive Officer | Exercise or conversion | +20,000 | $2.08 | $42K | 502,199 |
| 2022-05-03 | Mainolfi Nello Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −20,000 | 46,424 | ||
| 2022-05-03 | Jacobs Bruce N. Chief Financial Officer | Exercise or conversion | +20,000 | $2.08 | $42K | 60,814 |
| 2022-05-03 | Jacobs Bruce N. Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) | −20,000 | 159,899 | ||
| 2022-03-01 | Mainolfi Nello Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +275,100 | 275,100 |
Page 38 of 41 · 810 trades